✦ LIBER ✦

Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer

✍ Scribed by Kenji Katsumata; Hidenori Tomioka; Mikihiro Kusama; Tatsuya Aoki; Yasuhisa Koyanagi

Publisher: Springer
Year: 2003
Tongue: English
Weight: 149 KB
Volume: 52
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-003-0586-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination chemotherapy of metastatic b

Combination chemotherapy of metastatic breast cancer with vincristine, adriamycin and prednisolone

✍ J. A. Russell; J. W. Baker; P. J. Dady; H. T. Ford; J. C. Gazet; J. A. McKinna; 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB 👁 2 views

Mitoxantrone combined to vincristine, cy

Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer

✍ R. Metz; M. Delgado; R. Keiling; P. Cappelaere; J. P. Armand; G. Prevot; J. L. M 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 301 KB

In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on

Advanced breast cancer: A randomized stu

Advanced breast cancer: A randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine

✍ J. A. Green; A. J. Slater; I. R. Campbell; V. Kelly 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 676 KB

The effects of multiple combination chem

The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer

✍ Tetsuhito Kojima; Akira Hoshino; Kanji Ohara; Osamu Kamiya; Koichiro Nagata; Yos 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 428 KB

First-line combination chemotherapy with

First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer

✍ P. Periti; G. Robustelli Delia Cuna; F. Pannuti; T. Mazzei; P. Preti; A. Martoni 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 312 KB

In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3-4 weeks, for a maximum of 12 cycles. The over

Pharmacokinetic, biochemical and clinica

Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide–bischloroethylnitrosourea combination therapy in patients with advanced breast cancer

✍ Mark Clemons; Malcolm Ranson; Jennifer M. Margison; Hassan El Teraifi; Audrey Gr 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 107 KB

## Abstract We assessed whether split dosing with the methylating agent DTIC is an effective strategy for inactivating the DNA repair protein __O__6‐alkylguanine DNA‐ATase in order to decrease tumour resistance to BCNU. ATase levels in PBMCs were used as a surrogate for tumour ATase depletion to de